国际标准期刊号: 2157-2526

生物恐怖主义和生物防御杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 研究圣经
  • 中国知网(CNKI)
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

AI-based scalable breast cancer screening solution in resource-constrained settings

Lakshmi Krishnan

Cancer of the breast is the most common cause of cancer-related deaths in India. Detecting breast cancer at early stages is critical for providing early treatment and thereby reducing disease morbidity and mortality. Mammography is the only screening method proved by randomized trials to reduce breast cancer mortality. However, it is less sensitive in women with dense breasts, and hence, its usage is limited in Asian countries where breast cancer is being increasingly detected in younger pre-menopausal women. Moreover, in India, where breast cancer screening is recommended at district hospitals (DHs), there are just 55 mammography machines at Government DHs to cater to 763 districts. Apart from increasing screening uptake at DHs, it is also necessary to make screening accessible at community health centres (CHCs). In a resource constrained setting, the cost of the equipment and high-skill requirement for interpretations makes mammography less affordable and feasible as a routine screening method. The more affordable clinical breast examination suffers from inconsistent results and late detection. Niramai’s Thermalytix™ is an AI-based solution that has demonstrated high sensitivity for screening breast cancers. This automated test is affordable, accessible, scalable for population-level screening and has already been used to screen over 30,000 women. However, loss to follow-up and risk perception in the asymptomatic population remains a barrier for large-scale screening programmes. This can be addressed by taking a holistic approach and combining screening of the top three cancers: breast, cervical, and oral cancers, along with other major noncommunicable diseases such as cardio-vascular disease, stroke, and diabetes at the CH